Anji Pharmaceuticals Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 9 to 20, 2026 · next Dec 9
- 1 fee due Mar 19, 2027The maintenance fee for Biguanide compositions and methods of treating metabolic disorders (US 11,759,441) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Jun 15, 2027The maintenance fee for Compositions and methods of treating metabolic disorders (US 9,211,263) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Compositions and methods for treating metabolic disorders (US 10,603,291) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Chemosensory Receptor Ligand-Based Therapies (US 10,610,500) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Compositions and methods for treating metabolic disorders (US 11,974,971) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,796,338 | Biguanide compositions and methods of treating metabolic disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,050,292 | Chemosensory Receptor Ligand-Based Therapies In force · Medium confidence | In force | Medium confidence | |
| US 9,463,170 | Chemosensory Receptor Ligand-Based Therapies In force · Medium confidence | In force | Medium confidence | |
| US 9,480,663 | Biguanide compositions and methods of treating metabolic disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,481,642 | Biguanide compositions and methods of treating metabolic disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,572,784 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk In force · From the USPTO record | In force | From the USPTO record | |
| US 9,770,422 | Compositions and methods for treating metabolic disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 9,962,344 | Chemosensory Receptor Ligand-Based Therapies In force · Medium confidence | In force | Medium confidence | |
| US 10,028,923 | Biguanide compositions and methods of treating metabolic disorders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,154,972 | Biguanide Compositions and Methods of Treating Metabolic Disorders In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 20: 4 patents in force now held by others · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 1 no status recorded